Download PDF
Erfahrungsheilkunde 2023; 72(03): 139-146
DOI: 10.1055/a-2080-3728
Praxis

Welche Rolle spielt Magnesium beim metabolischen Syndrom?

Daniela Birkelbach
› Further Information
    Permissions and Reprints

Zusammenfassung

Rund 30 % der Bevölkerung leiden unter dem metabolischen Syndrom, was als Risikofaktor für die Entwicklung eines Typ-2-Diabetes und weiterer diabetischer Folge- und Begleiterkrankungen gilt. Neben den gravierenden gesundheitlichen Problemen für die Patient*innen verursachen das metabolische Syndrom und seine Folgeerkrankungen hohe Kosten für das Gesundheitswesen: „Die stetige Zunahme der Zahl der Patienten mit metabolischem Syndrom und seinen Folgen ist eine schwerwiegende medizinische, soziale und ökonomische Herausforderung“, warnt in diesem Zusammenhang auch Prof. Hans Georg Classen, Vorsitzender der Gesellschaft für Biofaktoren e. V. (GfB). Ein zusätzliches Problem: Viele potenziell Erkrankte ahnen nichts von dem erhöhten Risiko. Neben der Optimierung von Stoffwechseleinstellung und Lebensweise können betroffene Patient*innen auch von einer zielgerichteten Versorgung mit essenziellen Biofaktoren wie Magnesium profitieren. Ein Mangel kann auch anderen Symptomen zugrunde liegen. Bei Magnesiummangelverdacht sollte daher immer eine Labordiagnostik erfolgen.

Abstract

Around 30% of the population suffers from metabolic syndrome, which is considered a risk factor for the development of type 2 diabetes and other diabetic secondary and concomitant diseases. In addition to the serious health problems for patients, the metabolic syndrome and its secondary diseases cause high costs for the health care system: “The steady increase in the number of patients with metabolic syndrome and its consequences is a serious medical, social and economic challenge”, also warns Prof. Hans Georg Classen, Chairman of the Gesellschaft für Biofaktoren e. V. (GfB), in this regards. An additional problem: Many potentially ill people are unaware of the increased risk. In addition to optimizing metabolic control and lifestyle, affected patients can also benefit from a target-oriented supply of essential biofactors such as magnesium. A deficiency may also be the cause of other symptoms. Therefore, laboratory diagnostics should always be performed if magnesium deficiency is suspected.

Schlüsselwörter

Magnesium - metabolisches Syndrom - Diabetes mellitus Typ 2 - Insulinresistenz - Biofaktorenmangel

Key words

Magnesium - metabolic syndrome - type 2 diabetes mellitus - insulin resistance - biofactor deficiency


Publication History

Article published online:
13 June 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37 (12) 1595-1607
    CrossrefPubMedGoogle Scholar
  • 2 Deutsche Diabetes Gesellschaft (DDG), diabetesDE – Deutsche Diabetes-Hilfe. Hrsg. Deutscher Gesundheitsbericht Diabetes 2023. Die Bestandsaufnahme. Im Internet: Accessed May 02, 2023 at: https://www.diabetesde.org/system/files/documents/gesundheitsbericht_2023_final.pdf
    PubMedGoogle Scholar
  • 3 Otte C. Einfluss von Depression und Antidepressiva auf Adipositas, metabolisches Syndrom und Diabetes mellitus Typ 2. Psychopharmakother 2017; 24: 204-210
    PubMedGoogle Scholar
  • 4 Schmid SM, Hallschmid M, Schultes B. The metabolic burden of sleep loss. Lancet Diab Endocrinol 2015; 3 (01) 52-62
    CrossrefPubMedGoogle Scholar
  • 5 Jansen J, Karges W, Rink L. Zinc and diabetes — clinical links and molecular mechanisms. J Nutr Biochem 2009; 20: 399-417
    CrossrefPubMedGoogle Scholar
  • 6 Cefalu WT, Hu FB. Role of chromium in human health and in diabetes. Diab Care 2004; 27 (11) 2741-2751
    CrossrefPubMedGoogle Scholar
  • 7 de Groot-Kamphuis DM, van Dijk PR, Groenier KH. et al. Vitamin B12 deficiency and the lack of its consequences in type 2 diabetes patients using metformin. Neth J Med 2013; 71 (07) 386-390
    PubMedGoogle Scholar
  • 8 Damião CP, Rodrigues AO, Castellar Pinheiro AFM. et al. Prevalence of vitamin B12 deficiency in type 2 diabetic patients using metformin: A cross-sectional study. Sao Paulo Med J 2016; 134 (06) 473-479
    CrossrefPubMedGoogle Scholar
  • 9 Ziegler D. Praxisempfehlungen der Deutschen Diabetes Gesellschaft. Stuttgart: Thieme; 2020
    Google Scholar
  • 10 Rodríguez-Morán M, Simental-Mendía LE, Gamboa-Goméz CI. et al. Oral magnesium supplementation and metabolic syndrome: A randomized double-blind placebo-controlled clinical trial. Adv Chronic Kidney Dis 2018; 25 (03) 261-266
    CrossrefPubMedGoogle Scholar
  • 11 Dibaba DT, Chen C, Lu L. et al. Magnesium intake is inversely associated with the risk of metabolic syndrome in the reasons for geographic and racial differences in stroke (REGARDS) cohort study. Clin Nutr 2021; 40 (04) 2337-2342
    CrossrefPubMedGoogle Scholar
  • 12 Gröber U, Kisters K, Gremmler B. et al. Ionized magnesium deficiency in elderly hypertensive patients in a pilot study. Nutr Food Sci J 2020; 3 (02) 129-134
    PubMedGoogle Scholar
  • 13 Micke O, Vormann J, Classen H-J. et al. Magnesium – Bedeutung für die hausärztliche Praxis. Positionspapier der Gesellschaft für Magnesium-Forschung e. V. Dtsch Med Wochenschr 2020; 145 (22) 1628-1634
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Song Y, Sesso HD, Manson JAE. et al. Dietary magnesium intake and risk of incident hypertension among middle-aged and older US women in a 10-year follow-up study. Am J Cardiol 2006; 98: 1616-1621
    CrossrefPubMedGoogle Scholar
  • 15 Verma H, Garg R. Effect of magnesium supplementation on type 2 diabetes associated cardiovascular risk factors: A systematic review and meta-analysis. J Hum Nutr Diet 2017; 30: 621-633
    Google Scholar
  • 16 Kass L, Weekes J, Carpenter L. et al. Effect of magnesium supplementation on blood pressure: A meta-analysis. Eur J Clin Nutr 2012; 66: 411-418
    CrossrefPubMedGoogle Scholar
  • 17 Zhang X, Yufeng L, Del Gobbo LC. et al. Effects of magnesium supplementation on blood pressure. A meta-analysis of randomized double-blind placebo-controlled trials. Hypertension 2016; 68 (02) 324-333
    CrossrefPubMedGoogle Scholar
  • 18 Kisters K, Classen HG. Magnesiumhaushalt und Therapie bei Hypertonie. Nier Hochdr Krankh 2020; 1: 245-251
    CrossrefPubMedGoogle Scholar
  • 19 Gröber U, Schmidt J, Kisters K. Magnesium in prevention and therapy. Nutrients 2015; 7 (09) 8199-8226
    CrossrefPubMedGoogle Scholar
  • 20 Simental-Mendía LE, Sahebkar A, Rodríguez-Morán M. et al. A systematic review and meta-analysis of randomized controlled trials on the effects of magnesium supplementation on insulin sensitivity and glucose control. Pharmacol Res 2016; 111: 272-282
    CrossrefPubMedGoogle Scholar
  • 21 Veronese N, Demurtas J, Pesolillo G. et al. Magnesium and health outcomes: An umbrella review of systematic reviews and meta-analyses of observational and intervention studies. Eur J Nutr 2020; 59 (01) 263-272
    CrossrefPubMedGoogle Scholar
  • 22 Kisters K, Gröber U. Magnesium in health and disease. Plant Soil 2013; 368: 155-165
    CrossrefPubMedGoogle Scholar
  • 23 Arpaci D, Tocoglu AG, Ergenc H. et al. Associations of serum magnesium levels with diabetes mellitus and diabetic complications. Hippokratia 2015; 19 (02) 153-157
    PubMedGoogle Scholar
  • 24 Jansen van Juren JM, Pillay S, Jansen van Juren CJ. Relationship between magnesium and lipids in patients with diabetes mellitus. J Endocrin Metabol Diab South Africa. 2019 Im Internet: Accessed May 02, 2023 at: https://www.tandfonline.com/doi/pdf/10.1080/16089677.2019.1585069
    PubMedGoogle Scholar
  • 25 Rocha Dos Santos L, Rodrigues de Sousa Melo S, Soares Severo J. et al. Cardiovascular diseases in obesity: What is the role of magnesium?. Biol Trace Elem Res 2021; 199 (11) 4020-4027
    CrossrefPubMedGoogle Scholar
  • 26 Elin RJ. Assessment of magnesium status for diagnosis and therapy. Magnes Res 2010; 23 (04) 194-198
    PubMedGoogle Scholar
  • 27 Workinger JL, Doyle RP, Bortz J. et al. Challenges in the diagnosis of magnesium status. Nutrients 2018; 10 (09) 1202
    CrossrefPubMedGoogle Scholar
  • 28 GANZIMMUN Diagnostics. Im Internet: Accessed May 02, 2023 at: http://www.ganzimmun.de
    PubMedGoogle Scholar
  • 29 Vormann J. Wie lässt sich ein Magnesiummangel nachweisen?. J Ernährungsmed 2001; 3 (04) 19-23
    PubMedGoogle Scholar
  • 30 Nielsen FH. Dietary magnesium and chronic disease. Adv Chron Kidney Dis 2018; 25 (03) 230-235
    CrossrefPubMedGoogle Scholar
  • 31 Walker AF, Marakis G, Christie S. et al. Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study. Magnes Res 2003; 16 (03) 183-191
    PubMedGoogle Scholar
  • 32 Stepura OB, Martynow AI. Magnesiumorotat in severe congestive heart failure (MACH). Int J Cardiol 2009; 131 (02) 293-295
    CrossrefPubMedGoogle Scholar
  • 33 Kisters K, Gremmler B, Schmidt J. et al. Positiver Effekt einer Magnesiumorotat-Therapie bei hypertensiver Herzerkrankung. Nier Hochdr Krankh 2016; 1: 1-6
    PubMedGoogle Scholar
  • 34 Blancquaert L, Vervaet C, Derave W. et al. Predicting and testing bioavailability of magnesium supplements. Nutrients 2019; 11 (07) 1663
    CrossrefPubMedGoogle Scholar